Protein kinase CK2 (formerly casein kinase II or 2) is known to play a critical role in the control of cell growth and cell death and is thus intimately involved in the development of cancer. More specifically, CK2 has been found to be elevated in all cancers examined. While CK2 levels are known to be high in proliferating normal cells, CK2 has also been found to be a potent suppressor of apoptosis and is a link to the cancer cell phenotype, which is characterized by deregulation of both cell proliferation and cell death. Indeed, it would appear that CK2 impacts many of the hallmarks of cancer and it has now gained considerable attention as a potential target for cancer therapy. Protein Kinase CK2 and Cellular Function in Normal and Disease States increases knowledge of the role of CK2 in the development of cellular dysfunction and emphasizes that this protein may serve as a target of drug development for improved cancer therapy. In addition, it is a handy tool that provides cancer researchers, graduate students, and all scientists involved in CK2 research with one main source for the latest advances in CK2 research. ?
|
Part I Regulation and Structure-Function Studies of CK2 |
|
|
|
Yeast Asf1 Protein as Modulator of Protein Kinase CK2 Activity |
|
|
3 | (14) |
|
|
|
|
|
|
|
Impressions from the Conformational and Configurational Space Captured by Protein Kinase CK2 |
|
|
17 | (18) |
|
|
|
|
|
|
|
|
|
Structural Basis of CK2 Regulation by Autoinhibitory Oligomerization |
|
|
35 | (14) |
|
|
|
|
|
Maize RNA-Binding Protein ZmTGH: A New Partner for CK2β1 Regulatory Subunit |
|
|
49 | (10) |
|
Isabel Cristina Velez-Bermudez |
|
|
|
|
Part II CK2 Control of Organismal and Cellular Functions |
|
|
|
CK2 in Organ Development, Physiology, and Homeostasis |
|
|
59 | (22) |
|
|
|
|
|
|
|
Protein Kinase CK2: A Window into the Posttranslational Regulation of the E(spl)/HES Repressors from Invertebrates and Vertebrates |
|
|
81 | (28) |
|
|
|
|
|
|
|
|
|
|
|
Tissue-Specific Functions and Regulation of Protein Kinase CK2 |
|
|
109 | (16) |
|
|
|
|
|
|
|
|
|
|
|
CK2 Function in the Regulation of Akt Pathway |
|
|
125 | (16) |
|
|
|
|
|
Cellular Zinc Signalling Is Triggered by CK2 |
|
|
141 | (18) |
|
|
|
|
|
CK2: A Global Regulator of Cell Death |
|
|
159 | (24) |
|
|
|
|
|
|
|
|
|
Protein Kinase CK2: Systematic Relationships with Other Posttranslational Modifications |
|
|
183 | (14) |
|
|
|
|
|
Role for Protein Kinase CK2 on Cell Proliferation: Assessing CK2 Complex Components in the Nucleus During the Cell Cycle Progression |
|
|
197 | (30) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
"Genuine" Casein Kinase: The False Sister of CK2 That Phosphorylates Secreted Proteins at S-x-E/pS Motifs |
|
|
227 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Part III Function of CK2 in Cancer and Its Therapeutic Targeting |
|
|
|
Dysregulated Expression of Protein Kinase CK2 in Renal Cancer |
|
|
241 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Protein Kinase CK2 and Dysregulated Oncogenic Inflammatory Signaling Pathways |
|
|
259 | (22) |
|
|
|
|
|
|
|
CIGB-300: A Promising Anti-Casein Kinase 2(CK2) Peptide for Cancer Targeted Therapy |
|
|
281 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Targeting CK2 for Cancer Therapy Using a Nanomedicine Approach |
|
|
299 | (20) |
|
|
|
|
|
|
|
|
|
Part IV Studies Involving CK2 Small Molecule Inhibitors |
|
|
|
Screening of DTP Compound Libraries for CK2 Inhibitors with Focus on Natural Products |
|
|
319 | (22) |
|
|
|
|
|
|
|
CK2 Inhibitors and the DYRK Family Protein Kinases |
|
|
341 | (20) |
|
|
|
Sensitivity of Protein Kinase CK2 to ATP/GTP and Specific Inhibitors Depends on Complexity of Interacting Proteins |
|
|
361 | (14) |
|
|
|
|
| Index |
|
375 | |
Dr. Khalil Ahmed is a Professor at the University of Minnesota, and a Senior Research Career Scientist at Minneapolis VA Health Care System, Minneapolis, Minnesota, U.S.A. He has a long history of studies on the functional biology of protein kinase CK2 in normal and neoplastic cells. He originally described the signal mediated dynamic shuttling of CK2 in the cell, and discovered the role of CK2 as a suppressor of apoptosis. His current research is focused on the mechanism of CK2 regulation of cell death. He is also studying the development of molecular therapeutic strategies using a nanomedicine approach for treatment of prostate and other cancers.
Dr. Olaf-Georg Issinger is a Professor at the University of Southern Denmark, Odense, Denmark. He has been involved in the initial cloning and characterization of protein kinase CK2, a prerequisite for the elucidation of its structure in the absence and presence of specific interaction molecules. His current research focuses on the exploration of cellular signaling pathways in cell lines with respect to the role of various protein kinases using newly characterized kinase inhibitors identified by screening small chemical compound libraries.
Dr. Ryszard Szyszka is a Professor at the John Paul II Catholic University of Lublin, Poland. He is head of the Department of Molecular Biology and Dean of the Faculty of Biotechnology and Environmental Sciences. His research is focused on the identification and characterization of new substrates of protein kinase CK2 from Saccharomyces cerevisiae. Further areas of interest include the structure and regulation of yeast CK2, and discovery of novel CK2 inhibitors.
